Heron Therapeuti - Asset Resilience Ratio
Heron Therapeuti (HRTX) has an Asset Resilience Ratio of 7.58% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2025)
This chart shows how Heron Therapeuti's Asset Resilience Ratio has changed over time. Check how strategically is Heron Therapeuti's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Heron Therapeuti's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see HRTX market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $18.67 Million | 7.58% |
| Total Liquid Assets | $18.67 Million | 7.58% |
Asset Resilience Insights
- Limited Liquidity: Heron Therapeuti maintains only 7.58% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Heron Therapeuti Industry Peers by Asset Resilience Ratio
Compare Heron Therapeuti's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 57.90% |
|
TELIX Pharmaceuticals Ltd
AU:TLX |
Biotechnology | 32.29% |
|
Inner Mongolia Furui Med Sci
SHE:300049 |
Biotechnology | 2.34% |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX |
Biotechnology | 39.07% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
Annual Asset Resilience Ratio for Heron Therapeuti (2000–2025)
The table below shows the annual Asset Resilience Ratio data for Heron Therapeuti.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 7.03% | $17.98 Million | $255.88 Million | -7.33pp |
| 2024-12-31 | 14.36% | $33.48 Million | $233.15 Million | -8.89pp |
| 2023-12-31 | 23.25% | $51.73 Million | $222.51 Million | -4.44pp |
| 2022-12-31 | 27.69% | $69.49 Million | $250.95 Million | +5.76pp |
| 2021-12-31 | 21.93% | $67.04 Million | $305.71 Million | -7.30pp |
| 2020-12-31 | 29.23% | $103.35 Million | $353.56 Million | -32.99pp |
| 2019-12-31 | 62.22% | $319.07 Million | $512.78 Million | -2.80pp |
| 2018-12-31 | 65.03% | $300.54 Million | $462.18 Million | +53.16pp |
| 2017-12-31 | 11.86% | $27.80 Million | $234.31 Million | -44.04pp |
| 2016-12-31 | 55.90% | $37.72 Million | $67.48 Million | +15.29pp |
| 2015-12-31 | 40.62% | $55.99 Million | $137.84 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $76.68 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $75.94 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $55.97 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $19.45 Million | -- |
| 2008-12-31 | 4.84% | $571.00K | $11.80 Million | +0.64pp |
| 2007-12-31 | 4.20% | $1.55 Million | $36.95 Million | -72.25pp |
| 2006-12-31 | 76.45% | $13.19 Million | $17.25 Million | +20.49pp |
| 2005-12-31 | 55.96% | $5.02 Million | $8.97 Million | -5.67pp |
| 2004-12-31 | 61.63% | $10.49 Million | $17.01 Million | -9.73pp |
| 2003-12-31 | 71.36% | $9.39 Million | $13.15 Million | +10.46pp |
| 2002-12-31 | 60.90% | $10.84 Million | $17.80 Million | -6.64pp |
| 2001-12-31 | 67.54% | $15.88 Million | $23.51 Million | +8.16pp |
| 2000-12-31 | 59.38% | $16.03 Million | $27.00 Million | -- |
About Heron Therapeuti
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It … Read more